Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Autism charities merge to boost biomedical research efforts
The consolidation of the two charities is based on their joint commitment to accelerate and fund biomedical research into the causes, prevention, treatments and cure for autism spectrum
The consolidation of the two charities is based on their joint commitment to accelerate and fund biomedical research into the causes, prevention, treatments and cure for autism spectrum
Arformoterol tartrate is a long-acting beta-agonist formulation for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the US according to
Symadex was found to produce remyelination (repair of damaged myelin) in the study even after 40 days of inflammatory insult by preventing the infiltration of autoreactive cells into
The top line results show that none of the 36 patients enrolled in the study had a recurrence of liver function abnormalities that resulted in discontinuation of ambrisentan
Acrux describes what has been dubbed the ‘spay-on pill’, as a fourth-generation progestin contraceptive that has no androgenic hormonal effects, and a good safety profile. It says it
Under the terms of the agreement, Forest will make a $50 million upfront payment to Replidyne as well as potential future milestone payments. In addition, Replidyne will receive
In January 2005, CytRx announced the filing of a clinical protocol with the FDA to allow amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) patients who have completed
The approvals are for American Pharmaceutical Partners’ (APP) abbreviated new drug applications (ANDAs) for octreotide acetate injection, single-dose and multiple dose vials. Octreotide acetate injection is indicated for
QR-435 has demonstrated antiviral activity against ocular and genital herpes in preclinical studies at a US university, indicating a new R&D path for the versatile antiviral compound. Quigley
Pfizer said its 2006 revenues will be comparable to 2005, as growth of current and new products offsets revenue declines from loss of exclusivity and adverse foreign exchange.